Table 4 One-year univariate survival analysis.

From: Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change

Variable

Categories

Events/N

HR (95% CI)

p-value

1-year survival

Sex

Female

5/25

1.00

0.5

80 (58–91)

Male

10/34

1.49 (0.51–4.35)

69 (50–82)

Race

White

14/53

1.00

0.7

71 (57–83)

Black

1/5

0.68 (0.09–5.14)

80 (20–97)

AL subtype

Lambda

10/46

1.00

0.1

77 (62–87)

Kappa

5/13

2.36 (0.80–6.92)

60 (28–81)

2004 stage

I-II

2/31

1.00

0.002

93 (76–98)

IIIa

7/18

7.24 (1.50–34.88)

0.01

60 (34–79)

IIIb

6/8

17.46 (3.51–86.88)

0.0005

25 (4–56)

Stage 2012

1–2

1/27

1.00

0.002

96 (76–99)

3

7/20

10.58 (1.30–86.03)

0.03

62.5 (36–80)

4

7/10

33.42 (4.09–273.25)

0.001

30 (7–58)

Cardiac AL

No

0/20

100

Yes

15/39

NE

NE

59 (42–73)

Renal AL

No

6/25

1.00

0.9

76 (54–88)

Yes

9/34

1.07 (0.38–3.00)

71 (52–84)

Number of organs involved

1

3/21

1.00

0.02

86 (62–95)

2

4/23

1.24 (0.27–5.57)

0.8

81 (55–92)

3/+

8/15

5.03 (1.32–19.24)

0.02

39 (12–66)

  1. NE non-evaluable.